Role of sucralfate in peptic disease.
Sucralfate, a basic aluminum salt of sucrose, was the first successful drug with a major cytoprotective mechanism of action. It binds bile acids and pepsin and adheres to both ulcerated and nonulcerated mucosa. Sucralfate stimulates the synthesis and release of gastric mucosal prostaglandins as well as bicarbonate and the epidermal growth factor which stimulates healing. Sucralfate is the safest drug available today in the treatment of dyspeptic symptoms and compared to ranitidine and cimetidine it has the following characteristics. (2) The short-term healing of duodenal ulcers is the same for sucralfate, cimetidine and ranitidine. (3) Sucralfate-treated patients have a lower recurrence rate of duodenal ulceration after healing when compared with cimetidine and the recurrence rate is not connected with the presence or absence of Campylobacter pylori.
Jensen
S L
SL
Department of Surgical Gastroenterology L, Arhus Kommunehospital, University of Aarhus, Denmark.
Funch Jensen
P
P
D002927:Cimetidine / Q000627:therapeutic use; D004415:Dyspepsia / Q000188:drug therapy; D004942:Esophagitis, Peptic / Q000188:drug therapy*; D005756:Gastritis / Q000188:drug therapy*; D006801:Humans; D010437:Peptic Ulcer / Q000188:drug therapy* / Q000209:etiology / Q000517:prevention & control; D011899:Ranitidine / Q000627:therapeutic use; D012008:Recurrence; D013312:Stress, Physiological / Q000150:complications; D013392:Sucralfate / Q000009:adverse effects / Q000627:therapeutic use*; D014945:Wound Healing
D013392:Sucralfate; D002927:Cimetidine; D011899:Ranitidine